Zacks: Analysts Expect Cardiff Oncology, Inc. (NASDAQ:CRDF) Will Post Quarterly Sales of $80,000.00

Wall Street analysts expect Cardiff Oncology, Inc. (NASDAQ:CRDFGet Rating) to report $80,000.00 in sales for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Cardiff Oncology’s earnings, with the lowest sales estimate coming in at $50,000.00 and the highest estimate coming in at $100,000.00. Cardiff Oncology posted sales of $70,000.00 in the same quarter last year, which would indicate a positive year over year growth rate of 14.3%. The company is scheduled to issue its next quarterly earnings report on Monday, January 1st.

According to Zacks, analysts expect that Cardiff Oncology will report full-year sales of $300,000.00 for the current year, with estimates ranging from $200,000.00 to $400,000.00. For the next fiscal year, analysts anticipate that the business will post sales of $200,000.00. Zacks’ sales averages are an average based on a survey of sell-side research firms that that provide coverage for Cardiff Oncology.

Cardiff Oncology (NASDAQ:CRDFGet Rating) last announced its quarterly earnings results on Thursday, February 24th. The company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.06). Cardiff Oncology had a negative return on equity of 21.05% and a negative net margin of 7,880.50%.

Several brokerages recently weighed in on CRDF. William Blair started coverage on shares of Cardiff Oncology in a research report on Wednesday, January 5th. They issued an “outperform” rating on the stock. Zacks Investment Research cut shares of Cardiff Oncology from a “hold” rating to a “sell” rating in a research report on Wednesday, March 2nd. Maxim Group cut their price objective on shares of Cardiff Oncology from $25.00 to $14.00 in a research report on Monday, January 24th. Finally, HC Wainwright reiterated a “buy” rating and set a $25.00 price objective on shares of Cardiff Oncology in a research report on Tuesday. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, Cardiff Oncology currently has an average rating of “Buy” and an average price target of $16.25.

A number of hedge funds have recently bought and sold shares of the stock. Nisa Investment Advisors LLC bought a new stake in shares of Cardiff Oncology during the third quarter valued at approximately $47,000. Citigroup Inc. lifted its holdings in shares of Cardiff Oncology by 105.1% in the 4th quarter. Citigroup Inc. now owns 10,574 shares of the company’s stock worth $64,000 after buying an additional 5,419 shares during the period. Metropolitan Life Insurance Co NY purchased a new stake in shares of Cardiff Oncology in the 3rd quarter worth $74,000. Invesco Ltd. purchased a new stake in shares of Cardiff Oncology in the 2nd quarter worth $87,000. Finally, GSA Capital Partners LLP purchased a new stake in shares of Cardiff Oncology in the 4th quarter worth $93,000. 59.52% of the stock is currently owned by institutional investors.

CRDF traded down $0.05 during trading hours on Tuesday, hitting $2.08. The company’s stock had a trading volume of 446,717 shares, compared to its average volume of 798,212. The business’s 50-day moving average price is $2.65 and its 200-day moving average price is $4.70. Cardiff Oncology has a 12 month low of $2.06 and a 12 month high of $10.24. The stock has a market cap of $90.08 million, a price-to-earnings ratio of -2.93 and a beta of 1.84.

Cardiff Oncology Company Profile (Get Rating)

Cardiff Oncology, Inc, a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.

Recommended Stories

Get a free copy of the Zacks research report on Cardiff Oncology (CRDF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Cardiff Oncology (NASDAQ:CRDF)

Receive News & Ratings for Cardiff Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiff Oncology and related companies with MarketBeat.com's FREE daily email newsletter.